Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

“Gilead is fueling the next wave of innovation ... vital importance of catalyzing research reaching towards a cure.” Biktarvy Demonstrates High Rates of Viral Suppression in People with ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it presented encouraging long-term data from ALLIANCE study. ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Biktarvy maintained HIV-1 suppression in 95. ... with zero discontinuations due to TEAEs. Also Read: Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention At CROI 2025, the primary ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...

So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year. On the other hand, despite my concerns about Trodelvy, a targeted ...

Gilead Sciences, Inc. (NASDAQ ... The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen ...